Stocks · News reference
Teleflex (NYSE:TFX) lowers FY2026 GAAP EPS guidance from $2.90-$3.20 to $2.54-$2.84 vs $2.96 analyst estimate..
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Illumina (ILMN) raised its 2026 revenue and EPS guidance following a 9.5% year-over-year revenue increase in Q2, driven by strong oncology clinical growth and expanded multiomics offerings. However, the company faces margin pressure from tariffs, freight costs, and memory inflation, with adjusted gross margin declining 120 basis points year-over-year despite manageable leverage and sufficient liquidity.
Teleflex (TFX), a Zacks Rank #2 (Buy) stock, benefits from strong growth in its Vascular business driven by central access demand, hemostatic products, and FDA approval of EZPLAZ. The Interventional platform is expanding through the BIOTRONIK acquisition with promising clinical development of Freesolve. However, foreign exchange sensitivity remains a key concern. The company has improved balance sheet flexibility with net leverage declining to 1.9X following strategic divestitures.
The global fluoropolymer tubing market is projected to grow from $757.36 million in 2026 to $1.13 billion by 2032, at a CAGR of 6.85%. Growth is driven by demand from semiconductor, medical, pharmaceutical, battery, and aerospace industries, with opportunities emerging from high-purity requirements, miniaturization, and regulatory compliance. AI-enabled manufacturing and advanced extrusion technologies are enhancing production efficiency and quality control.
Top Wall Street analysts upgraded and raised price targets for FLNC, DT, NVDA, SNOW, TFX, COIN, and EXPE. See how other analysts view these stocks.